A new cancer fighting technology developed by Basar Bilgicer and Tanyel Kiziltepe, two professors with deep ties to the University of Notre Dame’s Advanced Diagnostics & Therapeutics (AD&T) initiative, is making a rapid and exciting transition to a real-world, commercialized product—one that could increase the effectiveness of cancer medications while lessening their toxic effects and improving patients’ quality of life.
The Precision Medicine technology is centered on ligand-targeted liposomes (LTLs), tiny bubble-like particles made from a phospholipid bilayer—the same molecules that comprise cell membranes. Using a new technique developed my Bilgicer, Kiziltepe, and others, the liposomes made by the team are much more consistent compared to the industry standard. This innovative format allows the components to be carefully incorporated during liposome synthesis and, in turn, drastically increases uniformity, which has been a major obstacle to the use of LTLs in personalized healthcare. Read More